BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 24862939)

  • 1. Mutation profile of differentiated thyroid tumours in an Australian urban population.
    Mond M; Alexiadis M; Fuller PJ; Gilfillan C
    Intern Med J; 2014 Aug; 44(8):727-34. PubMed ID: 24862939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
    Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT
    Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
    Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
    Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.
    Yip L; Nikiforova MN; Yoo JY; McCoy KL; Stang MT; Armstrong MJ; Nicholson KJ; Ohori NP; Coyne C; Hodak SP; Ferris RL; LeBeau SO; Nikiforov YE; Carty SE
    Ann Surg; 2015 Sep; 262(3):519-25; discussion 524-5. PubMed ID: 26258321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
    Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
    Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF (V600E) mutation analysis in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR.
    Jeong D; Jeong Y; Park JH; Han SW; Kim SY; Kim YJ; Kim SJ; Hwangbo Y; Park S; Cho HD; Oh MH; Yang SH; Kim CJ
    Ann Surg Oncol; 2013 Mar; 20(3):759-66. PubMed ID: 23179992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
    Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
    Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer.
    Howell GM; Carty SE; Armstrong MJ; Lebeau SO; Hodak SP; Coyne C; Stang MT; McCoy KL; Nikiforova MN; Nikiforov YE; Yip L
    Ann Surg Oncol; 2011 Dec; 18(13):3566-71. PubMed ID: 21594703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathologic and Clinical Characterization of Thyroid Tumors Carrying the BRAF(K601E) Mutation.
    Afkhami M; Karunamurthy A; Chiosea S; Nikiforova MN; Seethala R; Nikiforov YE; Coyne C
    Thyroid; 2016 Feb; 26(2):242-7. PubMed ID: 26422023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF mutations in an Italian cohort of thyroid cancers.
    Fugazzola L; Mannavola D; Cirello V; Vannucchi G; Muzza M; Vicentini L; Beck-Peccoz P
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):239-43. PubMed ID: 15272920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
    Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas.
    Sancisi V; Nicoli D; Ragazzi M; Piana S; Ciarrocchi A
    J Clin Endocrinol Metab; 2012 Sep; 97(9):E1745-9. PubMed ID: 22740704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
    Abubaker J; Jehan Z; Bavi P; Sultana M; Al-Harbi S; Ibrahim M; Al-Nuaim A; Ahmed M; Amin T; Al-Fehaily M; Al-Sanea O; Al-Dayel F; Uddin S; Al-Kuraya KS
    J Clin Endocrinol Metab; 2008 Feb; 93(2):611-8. PubMed ID: 18000091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Alterations in Differentiated Thyroid Cancer Patients with Acromegaly.
    Aydin K; Aydin C; Dagdelen S; Tezel GG; Erbas T
    Exp Clin Endocrinol Diabetes; 2016 Mar; 124(3):198-202. PubMed ID: 26575115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
    Erickson LA; Jin L; Nakamura N; Bridges AG; Markovic SN; Lloyd RV
    Cancer; 2007 May; 109(10):1965-71. PubMed ID: 17387744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [BRAF(T1799A) mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma].
    Cañadas Garre M; López de la Torre Casares M; Becerra Massare P; López Nevot MÁ; Villar Del Moral J; Muñoz Pérez N; Vílchez Joya R; Montes Ramírez R; Llamas Elvira JM
    Endocrinol Nutr; 2011 Apr; 58(4):175-84. PubMed ID: 21441079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RET/PTC rearrangement is prevalent in follicular Hürthle cell carcinomas.
    de Vries MM; Celestino R; Castro P; Eloy C; Máximo V; van der Wal JE; Plukker JT; Links TP; Hofstra RM; Sobrinho-Simões M; Soares P
    Histopathology; 2012 Nov; 61(5):833-43. PubMed ID: 22803838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational Analysis in Pediatric Thyroid Cancer and Correlations with Age, Ethnicity, and Clinical Presentation.
    Nikita ME; Jiang W; Cheng SM; Hantash FM; McPhaul MJ; Newbury RO; Phillips SA; Reitz RE; Waldman FM; Newfield RS
    Thyroid; 2016 Feb; 26(2):227-34. PubMed ID: 26649796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.